The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.
The treatment of mood disorders has been the subject of intense study for more than half a century and has resulted in the discovery and availability of a number of compounds that have seen tremendous success in the management of major depression and anxiety-related disorders. In spite of this success, these drugs have not provided a complete therapeutic solution for all patients and this has revitalised the need for a greater understanding of the underlying molecular mechanisms and targets involved in these disorders. Elucidation of these novel targets will enable the development of a better class of compounds which could benefit a greater majority of the patient population and be devoid of the current side effect liabilities. Towards that end, this review examines, in detail, the prospect of one such target, the corticotropin-releasing factor system, as having an enhanced therapeutic profile with the potential of a broader range of efficacy with reduced side effect liabilities.
Grigoriadis
Dimitri E
DE
Department of Pharmacology and Lead Discovery, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA. dgrigoriadis@neurocrine.com
D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000737:chemistry / Q000494:pharmacology*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018019:Receptors, Corticotropin-Releasing Hormone